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High mobility group box 1 (HMGB1) is a central mediator in inflammation and immunity. Recently, it was shown that different redox
states of the three cysteines of HMGB1 endow it with mutually exclusive activities, such as inducing chemotaxis or the transcription
of cytokines and chemokines, via the interaction with different receptors. The different HMGB1 redox forms can be identified by
mass spectrometry in body fluids of patients and may hold promise as biomarkers. We propose here a systematic nomenclature of
the different redox forms of HMGB1 and related proteins, to replace the conflicting names used so far by different laboratories.
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High mobility group box 1 (HMGB1)
is a 25-kDa nuclear protein that has attracted increasing interest as a mediator
of tissue damage and inflammation (1).
HMGB1 is released passively after cell
death and is secreted actively by
macrophages and many other cell types
during infection, injury or severe stress
(such as ischemia/reperfusion). Extracellular HMGB1 can act both as a chemoattractant for leukocytes, stem cells and
other cells involved in tissue repair and
as a proinflammatory mediator to induce both recruited leukocytes and
parenchymal cells to release tumor
necrosis factor (TNF)-α, interleukin
(IL)-1, IL-6 and other cytokines. Extracellular HMGB1 interacts with several receptors and partner proteins, including
receptor for advanced glycation endproducts (RAGE), Toll-like receptors
(TLRs) and the C-X-C motif chemokine

12( CXCL12), with which it forms a complex that binds the C-X-C chemokine receptor type 4 (CXCR4).
Recently, with the application of highresolution and sensitive proteomic mass
spectrometry, it has become apparent that
the different activities of HMGB1 depend
on multiple redox forms of three cysteine
residues within the protein (2,3). Indeed,
the different HMGB1 redox forms interact with different receptors, and there is
increasing attention to which redox form
of HMGB1 is responsible for specific
pathophysiological action. Moreover,
there is evidence that HMGB1, which is
predominantly fully reduced inside the
cell, can be oxidized in the cytoplasm
after ROS production (4,5). Thus, HMGB1
can now no longer be conceptualized as a
single protein species. At present, different laboratories refer to the different
HMGB1 redox forms in different ways. A
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unified nomenclature is thus required to
(a) facilitate interactions between various
laboratories, (b) expedite literature
searches and (c) avoid confusion, in particular, in sourcing the individual redox
forms from commercial providers. Even
more importantly, a unified nomenclature
will be important in the clinics: the different redox forms can be identified in the
body fluids of patients with several different complaints and might be used as
biomarkers for diagnosis, outcome prediction and rationally based therapeutic
decisions (6). Participants in the Merinoff
World Congress on HMGB1, held at the
Feinstein Institute for Medical Research
on October 9–11, 2013, thus decided to introduce a unified nomenclature.
Cysteine represents a potent nucleophile, and the chemistry of sulfur in protein cysteine residues is rich in complexity: the sulfur atom can exist in multiple
redox forms that can form bonds to another sulfur atom or to hydrogen, nitrogen, oxygen and carbon atoms. Furthermore, the identification of the chemical
form of cysteine sulfur in proteins often
involves the formation of chemical bonds
with specific reagents that form characteristic adducts; an effective nomenclature
also requires the facile identification of
such adducts. We therefore propose the
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Figure 1. Schematic structures of HMGB1, -2, -3 and -4. HMGB1 is a 25-kDa nuclear protein of 215 amino acids. The first methionine is
cleaved off posttranslationally. HMGB1 comprises two DNA-binding domains (blue), boxes A and B, and a negatively charged C-terminal
tail (red). The green boxes are connecting segments. The critical cysteines are highlighted in yellow. Box A, when isolated from the rest of
the molecule, acts as a specific antagonist of HMGB1. HMGB2, HMGB3 and HMGB4 have a similar overall domain organization, but are
products of different genes. No alternative protein products from alternative splicing are known.

adoption of a nomenclature that is based
on the name of the protein (HMGB1 or
one its family members, HMGB2, -3
and -4) and the amino acid number of the
cysteine residue in the polypeptide chain
(for example, C23), followed by a suffix
identifying the atom(s) or chemical group
bonded to the cysteine sulfur atom (for
example, “h” to indicate the formation of
a single bond to a hydrogen atom to generate the sulfhydryl moiety, “se” for the
formation of a chemical bond to one oxygen atom to form a sulfenic group, “so”
for the formation of chemical bonds to
three oxygen atoms to form a sulfonic
group, or “nem” to indicate the formation
of a chemical bond to nitrogen in the
N-ethylmaleimide group, which is used to
tag reduced cysteines in polypeptides).
Similarly, iodoacetamide has been used as
a tool to chemically characterize HMGB1
redox states by adding the carboxyamidomethyl group to the sulfur in
the protein; the suffix “iodo” can indicate
the formation of this chemical adduct.
This nomenclature is reminiscent of and
compatible with the nomenclature of posttranslational modifications of histones (7)
and other proteins (including HMGB1 itself) on noncysteine amino acid residues.
Indeed, HMGB1 can be acetylated or
methylated on lysines (K) and phosphorylated on serine/threonines (S/T). A special
case, not readily accommodated by the
current nomenclature of posttranslational
modifications, is the formation of a disul-

fide bond to another cysteine, because the
unequivocal identification of that specific
cysteine requires the indication of its
residue number as well. We propose the
suffix “-” (hyphen) connecting the cysteines involved in the disulfide bond. We
also propose that the absence of a specific
indication unequivocally indicates the absence of a posttranslational modification,
which in the case of cysteines would otherwise be indicated by the “h” suffix.
Fully reduced HMGB1 is thus identified
as “HMGB1C23hC45hC106h,” or more
simply “HMGB1,” since the protein is not
modified posttranslationally. HMGB1 containing a single intramolecular disulfide
bond between C23 and C45 and no posttranslational modification on C106 is to
be identified as “HMGB1C23-C45C106h,”
or more simply “HMGB1C23-C45,” since
the C106 residue is not modified posttranslationally. HMGB1 terminally oxidized to contain sulfonyl groups on all
cysteines should be identified as
HMGB1C23soC45soC106so.

This nomenclature also accommodates
HMGB1 adducts obtained after reaction
with specific chemical species, such as
HMGB1C23-C45C106nem or
HMGB1C23-C45C106iodo, which are obtained after reaction of the sulfhydryl
moiety on C106 within HMGB1C23-C45
with N-ethylmaleimide or iodoacetamide,
respectively. This nomenclature could
also accommodate chemical species not
currently identified in vivo or in vitro,
such as reaction products of cysteine sulfur with nitrogen oxide (for review of
cysteine S-nitrosylation, see [8]).
Figure 1 indicates the domain structure of HMGB1 and its family members;
we expect HMGB2 to undergo the same
posttranslational modification as
HMGB1, although so far these modifications have not been identified or even
been sought after. Table 1 shows a partial
list of atoms or groups that can be bound
to cysteine 23 of HMGB1; cysteines 45
and 106 follow the same rules. Table 2
lists the redox forms of HMGB1 that

Table 1. Suggested abbreviations for cysteine modifications.
Abbreviation of
modification
C23h
C23-C45
C23so
C23nem
C23iodo

Modification
R-SH
R-S-S-R
R-SO3–
R-S-NEM
R-S-carboxy-amidomethyl

Description
Thiol
Disulfide bond with cysteine 45
Sulfonate modification
Adduct after reaction with NEM
Adduct after reaction with iodoacetamide

The modification of cysteine 23 in HMGB1 is given as an example.
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Table 2. Redox forms of HMGB1 identified so far.
Complete notation

Simple identification

Description

HMGB1C23hC45hC106h

Fully reduced HMGB1

HMGB1 with no posttranslational modifications; predominant form in nucleus and
cytoplasm in basal conditions; forms a heterocomplex with CXCL12 that interacts
with receptor CXCR4 to promote cell migration

HMGB1C23-C45C106h

Disulfide HMGB1

HMGB1 with a disulfide bond connecting C23 and C45; interacts with receptor TLR4
to induce cytokine and chemokine transcription and secretion

HMGB1C23soC45soC106so

Sulfonyl HMGB1

Formed after exposure to ROS; has no activity for cell migration or cytokine induction

Figure 2. The functional activity of HMGB1 is regulated by its redox status. In its fully reduced form (HMGB1C23hC45hC106h), HMGB1
has cell migration–inducing activity but no cytokine-inducing activity. In its partly oxidized form, disulfide HMGB1 (HMGB1C23C45C106h) has no cell migration–induced activity but possesses cytokine-inducing activity. The terminally oxidized form, sulfonyl
HMGB1 (HMGB1C23soC45soC106so), has neither cell migration–inducing activity nor cytokine-inducing activity.

have been identified so far in vivo and
the biochemical and physiological activities that have been attributed to them,
and Figure 2 provides a pictorial representation of the various forms.
Recombinant box A and box B (Figure 1)
are important molecular research tools to
dissect the various functions of the
HMGB1 domains. Although the importance of the redox state of these molecules
has not been fully investigated to date,
the nomenclature system we propose
can be applied to the individual recombinant boxes as well. For example, fully
reduced box A or box B is identified as
“BoxAC23hC45h” and “BoxBC106h,” or
more simply box A or box B, since the
cysteine residue is not modified posttranslationally. Furthermore, as with the
full-length protein, an intramolecular
disulfide bond between C23 and C45 in
box A would be identified as BoxAC23C45. Box A or box B terminally oxidized
to contain sulfonyl groups on all cysteines
should be identified as BoxAC23soC45so
and BoxBC106so.

We propose to phase out all currently
used identifications of HMGB1 that do
not conform to this nomenclature and
thus might generate confusion. For use in
short abstracts or titles, where space is at
a premium, the terms “fully reduced
HMGB1,” “disulfide HMGB1” or “sulfonyl
HMGB1” are acceptable, but the systematic identification should be used in the
full text. For oral presentations, we similarly propose to use the terms “fully reduced HMGB1,” “disulfide HMGB1” or
“sulfonyl HMGB1” in speech, but at the
same time use the systematic identification in the projected images.
As we continue to move forward with a
consensus and understanding of HMGB1
functions, we are confident that the proposed nomenclature will bring clarity to
the entire burgeoning field of HMGB1 biology, and immunity in general.
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